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Background: D-lactate, one of the isomers of lactate, exists in a low concentra-
tion in healthy individuals and it can be oxidized to pyruvate catalyzed by D-
lactate dehydrogenase. Excessive amount of D-lactate causes D-lactate acidosis
associated with neurological manifestations.
Methods and Results: We report here a patient with developmental delay,
cerebellar ataxia, and transient hepatomegaly. Enzyme analysis in the patient's
skin fibroblast showed decreased mitochondrial complex IV activity. Using
whole exome sequencing, we identified compound heterozygous variants in
the LDHD gene, which encodes the D-lactate dehydrogenase, consisting of a
splice site variant c.469+1dupG and a missense variant c.752C>T, p.
(Thr251Met) which are pathogenic and likely pathogenic respectively
according to the American College of Medical Genetics and Genomics
(ACMG) classification. The serum D-lactate level was subsequently detected to
be elevated (0.61 mmol/L, reference value: 0-0.25 mmol/L).
Conclusion: This is the third report on LDHD mutations associated with
D-lactate elevation and was first reported to have decreased mitochondrial
complex IV activity. The study provides more information on this rare meta-
bolic condition but the association of LDHD deficiency with the clinical pre-
sentations requires further investigations.
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1 | INTRODUCTION
L-lactate and D-lactate exist as two different optical iso-
mers in the human body. L-lactate, produced from anaero-
bic glycolysis, has concentration 100 times higher than
D-lactate in circulation.1 Circulating D-lactate exists in a
very low concentration (5-20 μmol/L) in normal individ-
uals.2 It is derived from exogenous source including food
consumption, intestinal carbohydrate-fermenting bacteria
production, or endogenously in a minor methylglyoxal
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metabolism pathway converting toxic methylglyoxal to
D-lactate.3 D-lactate can be converted to D-pyruvate cata-
lyzed by D-lactate dehydrogenase which has been identi-
fied and well-characterized in lower organisms such as
bacteria and yeasts.4-6 Mammalian D-lactate dehydroge-
nase was later identified with high similarity to yeast
D-lactate dehydrogenase 1 with primary intracellular loca-
tion in mitochondria.7 A recent study demonstrated that
human wild-type LDHD encoding human D-lactate dehy-
drogenase, but not mutated LDHD from a patient, could
rescue the phenotype of D-lactate metabolism by LDHD
knockout zebrafish model and it provides evidence that
LDHD is responsible for human D-lactate metabolism.1
Lactic acidosis is a medical condition which is
resulted from the accumulation of excess lactate, usually
L-lactate, and proton in body fluids with poor clinical out-
comes.8 Comparing with L-lactate acidosis, D-lactate aci-
dosis is a relatively rare condition which is also known as
D-lactate encephalopathy.9 Both L-lactate and D-lactate
can pass the blood-brain barrier. Unlike its levorotary
counterpart, elevation of D-lactate has neurotoxic effects
resulting in neurological symptoms.9,10 The presenting
neurological signs of D-lactate encephalopathy include
slurred speech, ataxia, gait disturbance, altered mental
condition, and behavioral change which would often be
confused with primary neurological disorders.9
Recently, elevation of D-lactate associated with neuro-
logical phenotypes has been reported in two patients with
D-lactate dehydrogenase deficiency resulting from LDHD
mutations.1 So far, there are only two studies reporting
LDHD mutations associated with D-lactate elevation.1,11
Here, we report another patient with LDHD mutations
with increased serum D-lactate level. The patient pres-
ented with global developmental delay, ataxia, transient
hepatomegaly, and mitochondrial complex IV deficiency.
This is the third study of LDHD mutation associated with
high D-lactate level and first identification of mitochon-
drial complex deficiency in this disorder.
2 | CASE REPORT
2.1 | Clinical history
Our patient was 14 years old and born of a non-
consanguineous Chinese couple with no relevant family
history. She presented with global developmental delay
since infancy. Her Griffiths Mental Developmental Scale
at 32.5 months showed that her mental age was only
21 months. Mild hepatomegaly was detected since
28 months without an identifiable cause, which resolved
after 3 months. Mild cerebellar ataxia was detected at
5 years of age with resolution after 10. Central hypotonia
was mild all along. Her growth parameters including
head circumference, height, and weight have been along
the 50th to 75th percentile. The latest intellectual assess-
ment by Wechsler Intelligence Scale for Children-Fourth
Edition (Hong Kong) (WISC-IV) at 13 years old revealed
a full-scaled intelligence quotient of 76 which was in the
limited intelligence range. Magnetic resonance imaging
of the brain was normal. Liver function and ultrasonogra-
phy was normal. Currently, the patient is not put on any
dietary restrictions. She is studying in a mainstream
school with special educational needs for her learning
difficulty.
Metabolic workup showed intermittent hyperlactatemia
with highest lactate 3.22 mmol/L (0.55-2 mmol/L). The
plasma amino acid profile was unremarkable with normal
levels of branched chain amino acid. She had persistent
increase in lactate and organic acids excretion including
3-hydroxybuyrate, 2-hydroxyisovalerate, 2-hydroxy-
3-methylvalerate, and 2-hydroxyisocaproate in urine. Blood
uric acid was marginally raised at 316 μmol/L (normal
range: 105-300 μmol/L).
2.2 | Enzyme analysis
Measurements of pyruvate dehydrogenase (PDH) and
respiratory chain complex activities in the patient's skin
fibroblasts were performed at the Radboud Centre for
Mitochondrial Medicine, The Netherlands. It revealed
reduction in complex IV activity (221 mU/UCII; refer-
ence: 288-954). The enzyme measurements were repeated
in a new fibroblast culture and confirmed the mild com-
plex IV deficiency (259 mU/U CS; reference: 288-954).
Enzyme activities were repeatedly within normal ranges
for the other oxidative phosphorylation complexes
including complex I, complex II, complex III, succinate:
cytochrome c oxidoreductase, and complex V. Although a
PDH-E3 deficiency was suspected because of the
hyperlactatemia and raised branched chained amino acid
metabolites in the urine, both the activity of the PDH
holoenzyme and of PDH-E3 were within normal ranges.
2.3 | Genetic analysis
Whole exome sequencing (WES) and bioinformatics ana-
lyses were performed as described previously.12,13 The
variants called were annotated by Oncotator version
1.8.0.0 and filtered by first-tier variant analysis based on a
virtual gene panel associated with mitochondrial diseases
and with strong support of mitochondrial localization
suggested in MitoCarta 2.0. Compound heterozygous var-
iants were identified in the LDHD gene. These variants
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have been reported in our previous study on a patient
cohort suspicious of mitochondrial diseases.14 The vari-
ants were further confirmed by Sanger sequencing. One
of the variants was intronic within the splice site (c.469
+1dupG, NM_153486.3) (Figure 1A) which was predicted
to alternate wild-type donor site and most probably affect
splicing by online software Human Splicing Finder.15
Another variant was a missense one [c.752C>T, p.
(Thr251Met), NM_153486.3] (Figure 1A). Both variants
were not found in East Asian population according to
The Genome Aggregation Database (gnomAD). Sanger
sequencing of the identified variants in parental DNA
was performed and showed that the variants were segre-
gated between the parents. The father is the carrier of the
intronic splice site variant and the mother is the carrier
of the missense variant (Figure 1A).
In silico analysis including sorting intolerant from tol-
erant, Polyphen-2 and Mutation Taster also predicted that
this residue was located in highly conserved region and p.
(Thr251Met) was predicted to be damaging to the protein
structure and function. Multiple alignments of LDHD of
human, eight vertebrates and DLD1 of yeast were per-
formed by online Clustal Omega (1.2.4) multiple sequence
alignment software,16 the amino acid residue of Thr251
was highly conserved evolutionarily (Figure 1B). Using the
three-dimensional modeling by structure-based prediction
of protein stability changes upon single-point mutation,
the p.(Thr251Met) variant results a delta-delta G value of
2.0. A positive delta-delta G value implies the variant is
responsible for LDHD protein fold stabilization.17
According to ACMG classification,18 the frameshift variant
falls into the tier of “Pathogenic.” It was suggested that
nonsense mediated decay (NMD) degrades alternatively
spliced (AS) transcript with reading frameshift and prema-
ture translation-termination codon by a strategy called AS
coupled to NMD (AS-NMD).19 The missense variant falls
into the tier of “Likely pathogenic” with a Post_P value 0.9
using the Bayesian classification framework.20
2.4 | Reverse transcription polymerase
chain reaction
RNA was extracted from the patient's fibroblasts and semi-
quantitative reverse transcription polymerase chain reac-
tion was performed to amplify the LDHD complementary
DNA (cDNA) consisting of the region with the two vari-
ants found. Sanger sequencing of the cDNA revealed that
only the allele with the missense variant was expressed
while cDNA with the splice site variant was not identified
(Figure 1A). This finding illustrated that the mRNA with
the splice site variant could be eliminated by AS-NMD
which targets transcripts with the aberrant splicing.
2.5 | Quantitation of serum D-lactate
level
After identification of LDHDmutations, the patient's serum
D-lactate level was quantified in Mayo Clinic Laboratories.
D-lactate is oxidized to pyruvate in the presence of D-lactate
dehydrogenase and nicotinamide adenine dinucleotide
(NAD). The quantity of reduced NAD produced, which
was directly proportional to the level of D-lactate oxidized,
was measured spectrophotometrically at 340 nm.21,22
Serum D-lactate level was found to be higher than normal
(0.61 mmol/L; reference value: 0-0.25 mmol/L).
3 | DISCUSSION
3.1 | Comparisons of the previous two
studies of LDHD deficiency
This is the third study reporting LDHD mutations associ-
ated with D-lactate elevation. Comparisons of the clinical
presentation, metabolic profiles and genetic analyses of
the three studies are summarized in Table 1.
The LDHD mutations found in the first and second
study were homozygous LDHD variants because the
affected individuals are from consanguineous marriages.
These homozygous variants were identified by analysis of
homozygosity regions by SNP array in the first study1
and WES followed by filtration of homozygous variants
in the second study.11 Compound heterozygous LDHD
variants were identified in our patient through WES,
demonstrating that WES is a powerful molecular diag-
nostic tool for discovery of uncommon genetic defect in
unresolved rare diseases while the clinical signs are not
specific enough for targeted gene analysis.
The clinical presentation and metabolic profiles of
our patient were comparable to the two patients of the
first study.1 Both patient 1 and our patient showed del-
ayed development. Both patient 2 and our patient pres-
ented with central hypotonia. All three patients showed
increased circulating D-lactate level and elevation of spe-
cific organic acids in urine. The elevation of D-lactate
level could be explained by the mutation of LDHD
encoding for human D-lactate dehydrogenase and the
study of Monroe et al1 provided evidence that LDHD is
responsible for human D-lactate metabolism. The specific
pattern of urine organic acid in both studies also
suggested a role of LDHD in the metabolism of branched-
chained ketoacids but further studies are necessary to
clarify the metabolic pathway(s) involved.
Clinical presentation of the patient in the second
report11 is quite different from the patients in both the
first report and in our study. The affected members of the
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kindred presented with hyperuricemia and gout arthrop-
athy with no neurological symptoms reported. The circu-
lating D-lactate levels are higher than those reported in
the first study and in our study. This high D-lactate level
is comparable to the level reported in D-lactate acidosis in
short bowel syndrome but no neurological manifestation
FIGURE 1 Identification of human LDHD variants. A, Sanger sequencing of index patient, father and mother. Two LDHD heterozygous
variants, NM_153486.3: c.469+1dupG and c.752C>T, p.(Thr251Met) were confirmed by genomic DNA sequencing. Sanger sequencing of the
cDNA revealed that only one allele with the missense variant was expressed. Father is heterozygous carrier of the splice site variant c.469
+1dupG and the mother is heterozygous carrier of the missense variant p.(Thr251Met). Arrows point to the specific nucleotide changes. B,
Multiple alignments of LDHD amino acid sequences across yeast and different vertebrates showed that the variant p.(Thr251Met) encodes
for the amino acid methionine (Met) instead of the normally present amino acid threonine (Thr) in a region that is highly conserved. cDNA,
complementary DNA
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TABLE 1 Comparisons of clinical features, metabolic profiles, and genetic analysis of the three studies of LDHD deficiency
Monroe et al.1 Monroe et al.1 Drabkin et al.11 Our patient
Ancestry Sicilian village in Italy Moluccan in Indonesia Bedouin-Israeli Chinese
Parents Originated from the
same Sicilian village
share some degree of
consanguinity.
Consanguineous Consanguineous Nonconsanguineous
Age of onset of
symptoms and signs
1 y old 5 mo. old Gout arthropathy has
been reported in adult
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palms and toes, with

























acid in plasma and
urine







Uric acid Not mentioned Not mentioned Elevation of plasma uric
acid levels; Average
plasma uric acid levels
were 10.34 ± 1.84 mg/
dL (615 ± 109 μmol/L)
and 6.75 ± 0.7 mg/dL
(401 ± 42 umol/L) in
the affected adults and
children (normal
levels are 208-428 and
119-369 μmol/L)
Elevation of plasma uric




KWONG ET AL. 19
was reported. Organic acid level of the kindred has not
been measured. Blood uric acid of our patient was mar-
ginally raised at 316 μmol/L (normal 105-300 μmol/L)
and no gout arthropathy was identified. A possible expla-
nation is that our patient is still young and from the sec-
ond paper, they only reported that all affected adults
were clinically diagnosed with gout arthropathy and the
average uric acid level in children was also marginal
(401 ± 42 μmol/L; normal levels 119-369 μmol/L). Active
follow-up on the uric acid level with any joint involve-
ment will be essential for our patient. For the relation-
ship between D-lactate and uric acid elevation, previous
study suggested that lactate and organic acid including
beta-hydroxybutyrate may compete with and reduce the
renal clearance of uric acid leading to high level of serum
uric acid associated with gout.23-25
The clinical features in different reports are variable.
The kindred in the second report with the highest level of
D-lactate seems to have the mildest presentation, we
cannot exclude the possibility that the phenotypes are
resulted from other genetic defects rather than D-lactate
dehydrogenase deficiency as they have consanguineous
background. Besides, the neurological signs of the two
patients in the first study could be potentially explained
by the additional genetic defects identified. Despite this,
we cannot exclude the possible association of LDHD defi-
ciency with neurological phenotypes as D-lactic acidosis
has potential neurotoxic effects leading to neurological
symptoms. Other than the clinical presentations, the met-
abolic phenotypes can be well explained by LDHD muta-
tions in all the reports. More evidence and case studies
are required to support the relationship of LDHD defi-
ciency and clinical manifestations. Currently, trans-
criptomic analysis is ongoing in our patient to further
explore the underlying patho-mechanism of LDHD defi-
ciency and the possibility of mutation(s) involving a
second gene which could have explained the clinical
phenotype.
TABLE 1 (Continued)
Monroe et al.1 Monroe et al.1 Drabkin et al.11 Our patient
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3.2 | Ataxia, transient hepatomegaly,
and decrease in mitochondrial complex
IV activity
In addition to developmental delay and hypotonia, our
patient presented with ataxia which were not reported in
the previous cases. Ataxia is one of the common neuro-
logical manifestations presented during D-lactate acidosis
in patients with short bowel syndrome and other D-
lactate encephalopathy..9,26 Among these neurological
symptoms, ataxia was third common symptom of D-lactic
acidosis in 32% of patients with short bowel syndrome as
reviewed previously.9
Our patient also has transient mild hepatomegaly in
infancy without major precipitating causes such as infec-
tion. From GTEx expression data (https://www.
gtexportal.org/home) and result from the second study
using reverse transcription-polymerase chain reaction,11
human LDHD transcripts were abundant in tissues with a
high metabolic rate in which liver, skeletal muscle, heart,
and colon had the highest expression levels. D-lactate is
produced in the methylglyoxal pathway in the liver cyto-
sol.27 A previous study demonstrated that rat liver mito-
chondria can take up external D-lactate, metabolize it by
D-lactate dehydrogenase located in mitochondrial inner
membrane.28 In this way, D-lactate dehydrogenase is
essential for the removal of methylglyoxal which is toxic
to the liver and LDHD deficiency in our patient may be
the cause of hepatomegaly in infancy. However, her liver
function was all along normal. The reason for the tran-
sient nature of liver involvement remained elusive.
An interesting finding is the reduction of mitochon-
drial complex IV activity in our patient. Prior to the
enzyme measurements, the cells were cultured in cell
culture medium for several passages during which the
medium was refreshed several times. Therefore, it seems
unlikely that elevated D-lactate as observed in the
patient's plasma is responsible for the reduced complex
IV activity observed in the cultured fibroblasts. The asso-
ciation of D-lactate dehydrogenase with mitochondrial
respiratory chain has been studied in lower organisms
but not well known in mammals. Previous study in plant
suggested that D-lactate dehydrogenase delivered elec-
trons from methylglyoxal degradation to the respiratory
chain through cytochrome C.29 In bacteria, D-lactate
dehydrogenase contains a flavin adenine dinucleotide
(FAD) binding site for FAD cofactor transferring elec-
trons from the substrate oxidation to the electron trans-
port chain for ATP generation.30 In Saccharomyces
cerevisiae, mitochondrial LDHD has been shown to be
involved in methylglyoxal detoxification and to connect
D-lactate oxidation to the mitochondrial electron trans-
port chain.6 Mammalian LDHD was identified with high
similarity to yeast DLD1, including a potential FAD bind-
ing site.7 However, whether the enzyme is expressed in
fibroblasts is at present unknown. The mechanism
behind the interaction of the impaired D-lactate oxidation
pathway with the mitochondrial respiratory chain in
LDHD deficient patients deserves further investigations.
4 | CONCLUSION
In conclusion, the present study is the third report on
LDHD deficiency associated with D-lactate elevation. The
clinical features including ataxia, transient hepatomeg-
aly, and mitochondrial complex IV deficiency have not
been reported previously. The association of LDHD defi-
ciency with the neurological features and the additional
clinical presentations remained elusive. More case studies
on this metabolic condition are necessary to provide fur-
ther information on the potential phenotypic spectrum.
Although LDHD deficiency is a rare disease, it is still
worth considering for plasma D-lactate measurement and
urine organic acid analysis in patients with unexplained
neurological symptoms such as developmental delay, ataxia,
and epilepsy, as part of routine neurometabolic workup.
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